10 results on '"Kawabe, Junichi"'
Search Results
2. Nicotinic acetylcholine receptor [[alpha].sub.7] regulates cAMP signal within lipid rafts
- Author
-
Oshikawa, Jin, Toya, Yoshiyuki, Fujita, Takayuki, Egawa, Masato, Kawabe, Junichi, Umemura, Satoshi, and Ishikawa, Yoshihiro
- Subjects
Acetylcholine -- Receptors ,Biological sciences - Abstract
Neuronal nicotinic acetylcholine receptors (nAChRs) are made of multiple subunits with diversified functions. The nAChR [[alpha].sub.7]-subunit has a property of high [Ca.sup.2+] permeability and may have specific functions and localization within the plasma membrane as a signal transduction molecule. In PC-12 cells, fractionation by sucrose gradient centrifugation revealed that nAChR[[alpha].sub.7] existed in low-density, cholesterol-enriched plasma membrane microdomains known as lipid rafts where flotillin also exists. In contrast, nAChR [[alpha].sub.5]- and [[beta].sub.2]-subunits were located in high-density fractions, out of the lipid rafts. Type 6 adenylyl cyclase (AC6), a calcium-inhibitable isoform, was also found in lipid rafts and was coimmunoprecipitated with nAChR[[alpha].sub.7] Cholesterol depletion from plasma membranes with methyl-[beta]-cyclodextrin redistributed nAChR[[alpha].sub.7] and AC6 diffusely within plasma membranes. Nicotine stimulation reduced forskolin-stimulated AC activity by 35%, and this inhibition was negated by either treatment with [alpha]-bungarotoxin, a specific antagonist of nAChR[[alpha].sub.7], or cholesterol depletion from plasma membranes. The effect of cholesterol depletion was negated by the addition of cholesterol. These data suggest that nAChR[[alpha].sub.7] has a specific membrane localization relative to other nAChR subunits and that lipid rafts are necessary to localize nAChR[[alpha].sub.7] with AC within plasma membranes. In addition, nAChR[[alpha].sub.7] may regulate the AC activity via [Ca.sup.2+] within lipid rafts. cholesterol; PC-12 cells
- Published
- 2003
3. Impaired Glutathione Redox System Paradoxically Suppresses Angiotensin II-Induced Vascular Remodeling.
- Author
-
Izawa, Kazuma, Okada, Motoi, Sumitomo, Kazuhiro, Nakagawa, Naoki, Aizawa, Yoshiaki, Kawabe, Junichi, Kikuchi, Kenjiro, and Hasebe, Naoyuki
- Subjects
ANGIOTENSIN II ,GLUTATHIONE ,OXIDATIVE stress ,VASCULAR smooth muscle ,SPRAGUE Dawley rats ,BROMODEOXYURIDINE - Abstract
Background: Angiotensin II (AII) plays a central role in vascular remodeling via oxidative stress. However, the interaction between AII and reduced glutathione (GSH) redox status in cardiovascular remodeling remains unknown. Methods: In vivo: The cuff-induced vascular injury model was applied to Sprague Dawley rats. Then we administered saline or a GSH inhibitor, buthionine sulfoximine (BSO, 30 mmol/L in drinking water) for a week, subsequently administered 4 more weeks by osmotic pump with saline or AII (200 ng/kg/minute) to the rats. In vitro: Incorporation of bromodeoxyuridine (BrdU) was measured to determine DNA synthesis in cultured rat vascular smooth muscle cells (VSMCs). Results: BSO reduced whole blood GSH levels. Systolic blood pressure was increased up to 215±4 mmHg by AII at 4 weeks (p<0.01), which was not affected by BSO. Superoxide production in vascular wall was increased by AII and BSO alone, and was markedly enhanced by AII+BSO. The left ventricular weight to body weight ratio was significantly increased in AII and AII+BSO as compared to controls (2.52±0.08, 2.50±0.09 and 2.10±0.07 mg/g respectively, p<0.05). Surprisingly, the co-treatment of BSO totally abolished these morphological changes. Although the vascular circumferential wall stress was well compensated in AII, significantly increased in AII+BSO. The anti-single-stranded DNA staining revealed increasing apoptotic cells in the neointima of injured arteries in BSO groups. BrdU incorporation in cultured VSMCs with AII was increased dose-dependently. Furthermore it was totally abolished by BSO and was reversed by GSH monoethyl ester. Conclusions: We demonstrated that a vast oxidative stress in impaired GSH redox system totally abolished AII-induced vascular, not cardiac remodeling via enhancement of apoptosis in the neointima and suppression of cell growth in the media. The drastic suppression of remodeling may result in fragile vasculature intolerable to mechanical stress by AII. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Nicotinic acetylcholine receptor α[sub 7] regulates cAMP signal within lipid rafts.
- Author
-
Oshikawa, Jin, Toya, Yoshiyuki, Fujita, Takayuki, Egawa, Masato, Kawabe, Junichi, Umemura, Satoshi, and Ishikawa, Yoshihiro
- Subjects
NICOTINIC receptors ,CYCLIC adenylic acid ,LIPIDS - Abstract
Neuronal nicotinic acetylcholine receptors (nAChRs) are made of multiple subunits with diversified functions. The nAChR α[sub 7]-subunit has a property of high Ca[sup 2+] permeability and may have specific functions and localization within the plasma membrane as a signal transduction molecule. In PC-12 cells, fractionation by sucrose gradient centrifugation revealed that nAChRα[sub 7] existed in low-density, cholesterol-enriched plasma membrane microdomains known as lipid rafts where fiotillin also exists. In contrast, nAChR α[sub 5]- and β[sub 2]-subunits were located in high-density fractions, out of the lipid rafts. Type 6 adenylyl cyclase (AC6), a calcium-inhibitable isoform, was also found in lipid rafts and was coimmunoprecipitated with nAChRα[sub 7]. Cholesterol depletion from plasma membranes with methylβ-cyclodextrin redistributed nAChRα[sub 7] and AC6 diffusely within plasma membranes. Nicotine stimulation reduced forskolin-stimulated AC activity by 35%, and this inhibition was negated by either treatment with α-bungarotoxin, a specific antagonist of nAChRα[sub 7], or cholesterol depletion from plasma membranes. The effect of cholesterol depletion was negated by the addition of cholesterol. These data suggest that nAChRα[sub 7] has a specific membrane localization relative to other nAChR subunits and that lipid rafts are necessary to localize nAChRα[sub 7] with AC within plasma membranes. In addition, nAChRα[sub 7] may regulate the AC activity via Ca[sup 2+] within lipid rafts. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
5. Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits
- Author
-
Matsusaka, Tomoyuki, Hasebe, Naoyuki, Jin, Yin-Tie, Kawabe, Junichi, and Kikuchi, Kenjiro
- Subjects
MAGNESIUM ,MYOCARDIAL infarction ,ADENOSINES - Abstract
Objectives: Clinical impact of magnesium (Mg) therapy remains controversial in acute myocardial infarction. We investigated the infarct size limiting effects of Mg and its mechanism in rabbits. Methods: Anesthetized rabbits underwent 30 min coronary occlusion and 3 h reperfusion in ten groups: (1) Control, (2) Low Mg, (3) Mg, (4) High Mg, (5) calcium (Ca), (6) Mg+Ca, (7) 8-phenyltheophylline (8PT), an adenosine receptor blockade, (8) 8PT+Mg, (9) α, β-methylene-adenosine diphosphate (AOPCP), a selective inhibitor of ecto-5′-nucleotidase, and (10) AOPCP+Mg groups. Infract size (IS) to area at risk (AR) was measured by triphenyltetrazorium chloride method. Results: The IS/AR ratio was significantly smaller in Mg, 27±3% (P<0.05) and High Mg, 24±2% (P<0.05) compared to Control, 50±3% and Low Mg, 42±4%. The IS limiting effects of Mg were abolished in 8PT+Mg, AOPCP+Mg and Mg+Ca. The IS/AR ratio correlated with neither rate-pressure products nor incidence of arrhythmia. Conclusion: Magnesium administration has an infarct size limiting effect independent of its effects on myocardial oxygen consumption and incidence of arrhythmia in rabbits. The infarct size limiting effect of magnesium is attributable, at least in part, to augmentation of adenosine mechanism. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
6. Magnesium prevents catecholamine induced cardiac dysfunction and β-adrenergic down regulation
- Author
-
Jin, Yin-Tie, Hasebe, Naoyuki, Matsusaka, Tomoyuki, Natori, Shunsuke, Kawabe, Junichi, and Kikuchi, Kenjiro
- Published
- 1998
- Full Text
- View/download PDF
7. Brugada syndrome case: difficult differentiation between a concealed form and tricyclic antidepressant-induced Brugada sign.
- Author
-
Tashiro N, Sato N, Talib AK, Talib AK, Saito E, Okura M, Yamaki M, Nakagawa N, Sakamoto N, Ota H, Tanabe Y, Takeuchi T, Akasaka K, Kawabe J, Kawamura Y, and Hasebe N
- Subjects
- Adult, Brugada Syndrome physiopathology, Diagnosis, Differential, Humans, Male, Antidepressive Agents, Tricyclic adverse effects, Brugada Syndrome chemically induced, Brugada Syndrome diagnosis
- Abstract
We describe a case of Brugada syndrome, in which recurrent syncope with convulsive seizures was induced after antidepressant treatment. The patient had been treated with five kinds of psychotropic drugs. The twelve-lead ECG after the syncope exhibited an RSR'-pattern in the precordial leads, however, a coved type ST-segment elevation was induced by a pilsicainide test. Although ventricular fibrillation was not induced in the electrophysiologic study, an ICD implantation was considered as the recommended therapy since Brugada syndrome unmasked by antidepressants could not be ruled out. The possible contribution of antidepressants to Brugada type ST-segment changes is discussed.
- Published
- 2009
- Full Text
- View/download PDF
8. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
- Author
-
Sasaki T, Tanno S, Shibukawa K, Osanai S, Kawabe J, and Ohsaki Y
- Subjects
- Animals, Apoptosis drug effects, Carcinoma, Small Cell blood supply, Carcinoma, Small Cell metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Humans, In Situ Nick-End Labeling, Lung Neoplasms blood supply, Lung Neoplasms metabolism, Mice, Necrosis, Reverse Transcriptase Polymerase Chain Reaction, Vascular Endothelial Growth Factor A biosynthesis, Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors, Vascular Endothelial Growth Factor Receptor-2 drug effects, Xenograft Model Antitumor Assays, Carcinoma, Small Cell drug therapy, Lung Neoplasms drug therapy, Neovascularization, Pathologic drug therapy, Piperidines administration & dosage, Protein Kinase Inhibitors administration & dosage, Quinazolines administration & dosage, Vascular Endothelial Growth Factor A drug effects
- Abstract
Angiogenesis is mediated mainly by vascular endothelial growth factor (VEGF), and VEGF causes rapid growth in cancers, including human small-cell lung cancer (SCLC). The anti-angiogenic strategy of treating cancer using VEGF receptor (VEGFR) inhibition is currently of great interest. We tested the effects of the VEGFR2 tyrosine kinase inhibitor (TKI) vandetanib on the proliferation of two kinds of SCLC cell lines: SBC-1 cells, with detectable VEGFR2 expression and MS-1-L cells, without detectable VEGFR2 expression. To evaluate the anti-tumor and anti-angiogenic effects of vandetanib in vivo, we grafted SBC-1 and MS-1-L cells into mice. After a 3-week treatment, we measured the tumor size and histologically evaluated necrosis and apoptosis using H&E and TUNEL staining, respectively. The microvessels in the xenografts were also quantified by immunostaining of CD31. Vandetanib did not affect the proliferation of SBC-1 cells, but stimulated the growth of MS-1-L cells. In the SCLC xenograft model, vandetanib inhibited growth and tumor angiogenesis in a dose-dependent manner in SBC-1 xenografts. Vandetanib inhibited the growth of MS-1-L xenografts at a low dose (<12.5 mg/kg/day), but it did not affect tumor size or change microvessel counts at a higher dose. Interestingly, secretion of VEGF increased significantly in the MS-1-L cell line in the presence of a high dose of vandetanib in vitro. The effects of vandetanib on tumor angiogenesis were different in SBC-1 and MS-1-L cell lines. Production of angiogenic factors such as VEGF by the tumor potentially stimulates tumor angiogenesis and results in the acquisition of resistance to VEGFR TKI.
- Published
- 2008
9. Nicotinic acetylcholine receptor alpha 7 regulates cAMP signal within lipid rafts.
- Author
-
Oshikawa J, Toya Y, Fujita T, Egawa M, Kawabe J, Umemura S, and Ishikawa Y
- Subjects
- Adenylyl Cyclases metabolism, Animals, Cholesterol metabolism, Nicotine pharmacology, Nicotinic Agonists pharmacology, PC12 Cells, Rats, alpha7 Nicotinic Acetylcholine Receptor, Cyclic AMP metabolism, Membrane Microdomains metabolism, Receptors, Nicotinic metabolism
- Abstract
Neuronal nicotinic acetylcholine receptors (nAChRs) are made of multiple subunits with diversified functions. The nAChR alpha 7-subunit has a property of high Ca2+ permeability and may have specific functions and localization within the plasma membrane as a signal transduction molecule. In PC-12 cells, fractionation by sucrose gradient centrifugation revealed that nAChR alpha 7 existed in low-density, cholesterol-enriched plasma membrane microdomains known as lipid rafts where flotillin also exists. In contrast, nAChR alpha 5- and beta2-subunits were located in high-density fractions, out of the lipid rafts. Type 6 adenylyl cyclase (AC6), a calcium-inhibitable isoform, was also found in lipid rafts and was coimmunoprecipitated with nAChR alpha 7. Cholesterol depletion from plasma membranes with methyl-beta-cyclodextrin redistributed nAChR alpha 7 and AC6 diffusely within plasma membranes. Nicotine stimulation reduced forskolin-stimulated AC activity by 35%, and this inhibition was negated by either treatment with alpha-bungarotoxin, a specific antagonist of nAChR alpha 7, or cholesterol depletion from plasma membranes. The effect of cholesterol depletion was negated by the addition of cholesterol. These data suggest that nAChR alpha 7 has a specific membrane localization relative to other nAChR subunits and that lipid rafts are necessary to localize nAChR alpha 7 with AC within plasma membranes. In addition, nAChR alpha 7 may regulate the AC activity via Ca2+ within lipid rafts.
- Published
- 2003
- Full Text
- View/download PDF
10. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells.
- Author
-
Shiokoshi T, Ohsaki Y, Kawabe J, Fujino T, and Kikuchi K
- Subjects
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid pharmacology, Animals, Aorta cytology, Aorta drug effects, Benzoquinones pharmacology, Cells, Cultured, Cyclooxygenase 1, Cyclooxygenase 2, Down-Regulation, Enzyme Induction physiology, Heptanoic Acids pharmacology, Male, Membrane Proteins, Muscle, Smooth, Vascular cytology, Muscle, Smooth, Vascular drug effects, Nitric Oxide Synthase genetics, Nitric Oxide Synthase metabolism, Nitric Oxide Synthase Type II, Prostaglandin Antagonists pharmacology, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Receptors, Prostaglandin agonists, Receptors, Prostaglandin antagonists & inhibitors, Receptors, Thromboxane agonists, Receptors, Thromboxane antagonists & inhibitors, Receptors, Thromboxane A2, Prostaglandin H2, Aorta metabolism, Interleukin-1 pharmacology, Isoenzymes metabolism, Muscle, Smooth, Vascular metabolism, Nitric Oxide metabolism, Prostaglandin-Endoperoxide Synthases metabolism, Thromboxane A2 biosynthesis
- Abstract
Background: Cytokines from inflammatory cells do not produce nitric oxide, but stimulate the production of nitric oxide in vascular smooth muscle cells (VSMC). Thromboxane A2 (TXA2) has been believed to have a key role in atherosclerogenesis and post-angioplasty restenosis., Objective: To determine whether cytokine-induced nitric oxide production is regulated by the TXA2/prostaglandin H2 (PGH2) receptor., Methods and Results: We studied the interleukin-1beta (IL-1beta)-induced production of nitric oxide in rat VSMCs using the TXA2/PGH2 receptor antagonists, seratrodast and Bay-u3405, and an agonist, U-46619. Nitrite formation was measured colorimetrically. IL-1beta increased nitrite formation in a time-dependent manner. The nitrite concentration was 1.7 times greater in the presence of seratrodast than that without it. Nitrite accumulation was increased by Bay-u3405, but was decreased in the presence of U-46619, to 44% of that in its absence. Western and Northern blotting showed that seratrodast increased the levels of expression of inducible nitric oxide synthase (iNOS) protein and mRNA in a dose-dependent manner, whereas U-46619 decreased them. We speculated that VSMCs produced TXA2, thereby decreasing nitric oxide production; therefore we measured the accumulation of TXB2 using an enzyme immunoassay. Untreated VSMCs produced about 20 pg/mg protein of TXB2. This was increased by the addition of IL-1beta, to 152.1 +/- 43.0 pg/mg protein after a 24 h incubation; the expression of cyclooxygenase-2 (COX-2) protein was also increased, but there was no effect on the expression of COX-1 and TXA2 synthase. U-63557A, a TXA2 synthase inhibitor, increased the accumulation of nitrite to 1.3-fold that in its absence., Conclusions: These data suggest that the expression of iNOS and the production of nitric oxide are regulated by the TXA2/PGH2 receptor in IL-1beta-stimulated VSMCs. The endogenous production of TXA2 by the induction of COX-2 from IL-1beta-stimulated VSMCs probably downregulated the production of nitric oxide in VSMCs. TXA2/PGH2 receptor inhibitors may contribute to the reduction in formation of atherosclerosis in lesions with vascular injury by enhancing the production of nitric oxide by VSMCs.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.